编者按：免疫检查点抑制剂（ICI）作为肿瘤免疫治疗的一种新方式而广受关注, 但ICI通过调控免疫应答杀伤肿瘤的同时，过度活化的免疫细胞也可能致机体多个系统产生自身免疫损伤，即免疫相关不良反应。1型糖尿病虽然是较为罕见的免疫相关不良反应，但易发生危及生命的糖尿病酮症酸中毒，且多数需要终生依赖胰岛素治疗。随着临床免疫检查点抑制剂的广泛临床应用，免疫检查点抑制剂相关1型糖尿病（ICI-T1DM）的发生势必越来越多，应引起临床重视。在近期举办的2022中国医师协会内分泌代谢科医师年会上，来自南京医科大学第一附属医院的杨涛教授结合临床病例分享了ICI-T1DM的诊治进展。
从一个病例说起
内分泌不良反应是ICI最常见的不良反应之一
ICI-T1DM的流行病学
ICI-T1DM的遗传学特征
ICI-T1DM的免疫学特征
ICI-T1DM的临床特征
ICI-T1DM临床管理
总结与展望
参考文献
2、谷志远, 李薇, 杨涛, 刘晓云，陈家伟. 程序性死亡蛋白1抗体治疗后暴发性1型糖尿病一例 [J] . 中华糖尿病杂志, 2020, 12(5) : 328-332. DOI: 10.3760/cma.j.cn115791-20191022-00382.
3、施云, 沈敏, 顾愹, 杨涛. 免疫检查点抑制剂相关1型糖尿病 [J] . 中华糖尿病杂志,2020,12 (12): 945-948. DOI: 10.3760/cma.j.cn115791-20200706-00418.
4、Dougan M, Pietropaolo M. Time to dissect the autoimmune etiology of cancer antibody immunotherapy. The Journal of clinical investigation. 2020; 130(1): 51-61. DOI:10.1172/JCI131194.
5、Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54: 139-148. DOI:10.1016/j.ejca.2015.11.016.
6、Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(2): 173-182. DOI:10.1001/jamaoncol.2017.3064.
7、de Filette JMK, Pen JJ, Decoster L, et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. European journal of endocrinology / European Federation of Endocrine Societies. 2019; 181(3): 363-374. DOI:10.1530/EJE-19-0291.
8、Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018; 67(8): 1471-1480. DOI:10.2337/dbi18-0002.
9、Tsang VHM, McGrath RT, Clifton-Bligh RJ, et al. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. The Journal of clinical endocrinology and metabolism. 2019; 104(11): 5499-5506. DOI:10.1210/jc.2019-00423.
10、Kotwal A, Haddox C, Block M, et al. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019; 7(1): e000591. DOI:10.1136/bmjdrc-2018-000591.
11、Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clinical and experimental immunology. 2020. DOI:10.1111/cei.13424.
12、Wright JJ, Salem JE, Johnson DB, et al. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Diabetes care. 2018; 41(12): e150-e151. DOI:10.2337/dc18-1465.
13、Clotman K, Janssens K, Specenier P, et al. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. The Journal of clinical endocrinology and metabolism. 2018; 103(9): 3144-3154. DOI:10.1210/jc.2018-00728.
14、Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Current diabetes reports. 2011; 11(6): 533-542. DOI:10.1007/s11892-011-0223-x.
15、Gu Y, Zhang M, Chen H, et al. Discordant association of islet autoantibodies with high-risk HLA genes in Chinese type 1 diabetes. Diabetes/metabolism research and reviews. 2011; 27(8): 899-905. DOI:10.1002/dmrr.1270.
16、Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes care. 2015; 38(4): e55-57. DOI:10.2337/dc14-2349.
17、Yoneda S, Imagawa A, Hosokawa Y, et al. T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors. Diabetes care. 2019; 42(7): e116-e118.
18、Marchand L, Reffet S, Dalle S, et al. Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability Acta diabetologica. 2019; 56(3): 377-378. DOI:10.1007/s00592-018-1262-4.
19、Angelos K, Eka M, Wentin C, et al. Is immune checkpoint inhibitor-associated. diabetes the same as fulminant type 1 diabetes mellitus Clinical Medicine. 2020: 20(4): 417–23.DOI: 10.7861/clinmed.2020-0054.
20、Gunjur A, Klein O, Kee D, et al. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. J Immunother Cancer. 2019; 7(1): 241.
21、Shi Y, Shen M, Zheng XQ, et al. ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management. J Clin Endocrinol Metab.2020.Sep 9;dgaa553.
22、Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5(1): 95.
23、Castinetti F, Albarel F, Archambeaud F, et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer. 2019; 26(2): G1-G18.
24、Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018; 91: 21-29.
25、Akturk HK, Alkanani A, Zhao Z, et al. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. The Journal of clinical endocrinology and metabolism. 2018; 103(10): 3589-3592.
26、中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2015年版)[J]. 中华糖尿病杂志，2015，7(10):603-613. DOI: 10.3760/ cma.j.issn.16744-5809.2015.10.004.
27、中国医师协会内分泌代谢科医师分会，中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志，2017，33 ( 1 ) : 1-10.
（来源：《国际糖尿病》编辑部）
联系客服
